Fig. 9: Deployment of mFISHseq as a research-use only (RUO) test.

a Table outlining the number of genes and gene signatures and their relevant drug targets/pathways that were used for RUO testing. b Proportion of 48 patients according to treatment setting (left bar), consensus molecular subtype (middle bar, includes 58 samples total to account for 10 patients that had 2 subtypes collected by LCM), and TNBC subtype (right bar, contains 36 samples total comprised of 31 patients with 4 patients who had two subtypes collected by LCM and one patient that had both a primary and metastatic tumor analyzed). c Frequency of therapies that were recommended as the top three according to expression of genes and gene signatures tailored to each patient. Expression of 20 ADC antigen targets d as well as targets relevant to payloads for topoisomerase and microtubule inhibitors (e), endocytosis (f), lysosome activity (g), and resistance (h). The center line of the box and whisker plots represents the median, the box denotes the interquartile range, and the whiskers extend to the minimum and maximum values of the dataset. Dots show individual data points. i Examples of patients belonging to putative ADC treatment-responsive groups based on expression of ADC relevant biomarkers (shown as a percentile score). Patients 1, 18, 15, and 23 are predicted to respond to sacituzumab govitecan (SG), trastuzumab deruxtecan (T-DXd), both SG and T-DXd, and neither SG nor T-DXd, respectively. Note that these are hypothetical ADC treatment-responsive groups and no patients in the RUO cohort were recommended ADCs based on this framework. Source data are provided as a Source Data file.